The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12

Journal of Virology

Volumn 85, Issue 7, 2011, Pages 3642-3648

  Chaillon, Antoine ^a,b   Braibant, Martine ^a   Moreau, Thierry ^a   Thenin, Suzie ^a   Moreau, Alain ^a   Autran, Brigitte ^c   Barin, Francis ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY 2G12;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CELL CLONE; CLADISTICS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PSEUDOTYPING; SITE DIRECTED MUTAGENESIS; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS GENE; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952602584     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02424-10     Document Type: Article

References (39)

1. Binley, J. M., et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. (Pubitemid 39507829)
2. Braibant, M., et al. 2008. Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 47:274-284.
3. Braibant, M., et al. 2006. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20:1923-1930. (Pubitemid 44427609)
4. Braibant, M., et al. 2010. Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology 405:81-92.
5. Bunnik, E. M., L. Pisas, A. C. van Nuenen, and H. Schuitemaker. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
6. Calarese, D. A., et al. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U. S. A. 102:13372-13377.
7. Calarese, D. A., et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071. (Pubitemid 36760127)
8. Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
9. Dacheux, L., et al. 2004. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J. Virol. 78:12625-12637.
10. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
11. Doores, K. J., Z. Fulton, M. Huber, I. A. Wilson, and D. R. Burton. 2010. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain- exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J. Virol. 84:10690-10699.
12. Duenas-Decamp, M. J., and P. R. Clapham. 2010. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. J. Virol. 84:9608-9612.
13. Gray, E. S., P. L. Moore, R. A. Pantophlet, and L. Morris. 2007. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 81:10769-10776. (Pubitemid 47463349)
14. Hessell, A. J., et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
15. Hofmann-Lehmann, R., et al. 2001. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75:7470-7480. (Pubitemid 32738005)
16. Joseph, A., et al. 2010. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J. Virol. 84:6645-6653.
17. Katoh, K., G. Asimenos, and H. Toh. 2009. Multiple alignment of DNA sequences with MAFFT. Methods Mol. Biol. 537:39-64.
18. Koch, M., et al. 2003. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387-400. (Pubitemid 37045357)
19. Ly, A., and L. Stamatatos. 2000. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 74:6769-6776. (Pubitemid 30470659)
20. Manrique, A., et al. 2007. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81:8793-8808.
21. Mascola, J. R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
22. Montefiori, D. 2009. Optimization and validation of a neutralizing antibody assay for HIV-1 in TZM-bl cells using luciferase reporter gene expression. In Standardized assessments of neutralizing antibodies for HIV/AIDS vaccine development. Los Alamos National Laboratory, U.S. Department of Energy. Washington, DC. http://www.hiv.lanl.gov/content/nab-reference-strains/html/home. htm.
23. Montefiori, D. C. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays, chapter 12, unit 12-11. In J. E. Coligan (ed.), Current protocols in immunology. Wiley Interscience, New York, NY.
24. Montefiori, D. C. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485:395-405.
25. Nakowitsch, S., et al. 2005. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 19:1957-1966. (Pubitemid 41669019)
26. Pastore, C., et al. 2006. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J. Virol. 80:750-758. (Pubitemid 43062887)
27. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864. (Pubitemid 28175522)
28. Rong, R., et al. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81:1350-1359. (Pubitemid 46167856)
29. Sagar, M., X. Wu, S. Lee, and J. Overbaugh. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598. (Pubitemid 44435633)
30. Samleerat, T., et al. 2009. Maternal neutralizing antibodies against a CRF01-AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387:388-394.
31. Sanders, R. W., et al. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
32. Scanlan, C. N., et al. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha132 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
33. Scanlan, C. N., et al. 2003. The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv. Exp. Med. Biol. 535:205-218.
34. Trkola, A., et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622.
35. Trkola, A., et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108. (Pubitemid 26029030)
36. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
37. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
38. Wei, X., et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
39. Zhang, M., et al. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229-1246. (Pubitemid 39585357)